Arch Pharmalabs Limited, an Indian pharmaceutical company with a presence in the Active Pharmaceutical Ingredients (API) and intermediates segments, has acquired a majority stake in Benzochem Lifesciences Pvt. Limited, an Indian company, for an undisclosed amount. The acquisition provides Arch Pharmalabs access to a cGMP compliant facility for oncology products and enhances its portfolio to cover almost all therapeutic segments
Intas Biopharmaceuticals Limited, an Indian biopharmaceutical company, is acquiring Biologics Process Development Incorporated (BPD Inc.), a biotechnology company in the US. BPD Inc. is a Contract Research Organization (CRO) providing services in the area of Molecular Biology. The acquisition is expected to support Intas\' entry into the US market and strengthen its presence in the Contract Research and Manufacturing Services (CRAMS) segment.
Zydus Cadila, one of India\'s leading pharmaceutical companies, has acquired a 70 percent stake in Simayla Pharmaceuticals, a South Africa-based generics company. The acquisition is expected to strengthen Zydus\' presence in the South African generics market, which is expected to grow at a Compounded Annual Growth Rate (CAGR) of almost 19 percent till 2011. Simayla currently has a presence in the cardiovascular, respiratory, anti-infectives, central nervous system, gastrointestinal and women-related healthcare therapeutic segments. Zydus plans to launch about 50 products in this market in the next 3 years.
Daiichi Sankyo Company Limited, one of Japan\'s leading pharmaceutical companies, is acquiring a majority equity stake in Ranbaxy Laboratories Limited, India\'s largest pharmaceutical company and one of the top ten generics companies in the world.
Both companies have entered into a binding Share Purchase and Share Subscription Agreement, according to which, Daiichi Sankyo is expected to acquire the entire shareholding of the Singh family, one of the largest and controlling shareholders in Ranbaxy and further seek to acquire a majority of Ranbaxy\'s voting capital. The total transaction value is expected to be in the range of USD 3.4 billion to USD 4.6 billion. This transaction is expected to value Ranbaxy at USD 8.5 billion on the post closing basis. This deal is expected to enhance Ranbaxy\'s expertise in drug development and manufacturing and expand its global presenc.
Lupin Ltd announced that Dr. Raj Kamboj has joined the company as President – New Chemical Entity Research. This reflects the Company\'s commitment to continually strengthen its team by attracting the best talent globally. "We are very excited to have Raj join us as the Chief of our drug discovery program", Dr. D B Gupta, Chairman, Lupin Ltd. said. "He brings with him a vast pool of knowledge and experience which will be a great value add for Lupin\'s NCE research."
Headquartered in Mumbai, India, Lupin Limited is an innovation led transnational pharmaceutical company producing a wide range of quality, affordable generic and branded formulations and APIs for the developed and developing markets of the world.
The Company has secured global leadership position in Anti-TB and Cephalosporins and has a significant presence in the areas of Cardio-vasculars (prils and statins), Diabetology, Asthma and NSAIDs. The Company\'s R&D endeavors have resulted in significant progress in its NCE program. The Company\'s foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop valueadded generic pharmaceuticals. Currently positioned amongst the top six pharmaceutical companies of India, the Company is committed to achieve sustainable earnings and growth for all its stakeholders. For the financial year ended March 2008, the Lupin\'s Revenues and Profit after Tax were Rs.27, 730 million (US$ 694 million) andRs.4,083 million (US$ 102 million) respectively
